Sugar-free approaches to cancer cell killing

Oncogene

Volumn 30, Issue 3, 2011, Pages 253-264

  El Mjiyad, N ^a   Caro Maldonado, A ^a   Ramirez Peinado S ^a   Muoz Pinedo C ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

apoptosis; Bcl 2 proteins; cancer; glucose; tumor metabolism

Indexed keywords

BH3 PROTEIN; BIM PROTEIN; BUTYRIC ACID; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEATH RECEPTOR 4; DEOXYGLUCOSE; DEXAMETHASONE; DIAZEPAM; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FAS LIGAND; FLOXURIDINE; LONIDAMINE; METFORMIN; MITOMYCIN C; PACLITAXEL; PREDNISOLONE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN MCL 1; PUMA PROTEIN; TRICHOSTATIN A; TUMOR NECROSIS FACTOR; VINCRISTINE;

BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL DEATH; CELL KILLING; CELL STRAIN HEPG2; CELL STRAIN HT29; CELL STRAIN MCF 7; CELL STRAIN U937; CHEMOSENSITIZATION; COLON CARCINOMA; CYTOTOXICITY; DRUG EFFICACY; ENERGY RESOURCE; FIBROSARCOMA; GAMMA IRRADIATION; GLIOBLASTOMA; GLIOMA CELL; GLUCOSE METABOLISM; GLYCOLYSIS; GLYCOSYLATION; HEAD AND NECK CANCER; HELA CELL; HISTIOCYTIC LYMPHOMA; HUMAN; LEUKEMIA; LEUKEMIA CELL LINE; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; OVARY CARCINOMA; OXIDATIVE STRESS; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR REGRESSION;

APOPTOSIS; GLUCOSE; HUMANS; NEOPLASMS;

MAMMALIA;

EID: 78751648703     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.466     Document Type: Review

References (101)

1. Aft RL, Zhang FW, Gius D. (2002). Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. Br J Cancer 87: 805-812.
2. Alves NL, Derks IA, Berk E, Spijker R, Van Lier RA, Eldering E. (2006). The Noxa/Mcl-1 axis regulates susceptibility to apoptosis under glucose limitation in dividing T cells. Immunity 24: 703-716.
3. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P et al. (2010). Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 70: 2465-2475.
4. Boya P, Gonzalez-Polo R-A, Casares N, Perfettini J-L, Dessen P, Larochette N et al. (2005). Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 25: 1025-1040.
5. Buzzai M, Bauer DE, Jones RG, DeBerardinis RJ, Hatzivassiliou G, Elstrom RL et al. (2005). The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 24: 4165-4173.
6. Caro-Maldonado A, Tait SWG, Ramirez-Peinado S, Ricci JE, Fabregat I, Green DR et al. (2010). Glucose deprivation induces an atypical form of apoptosis mediated by caspase-8 in Bax-, Bak-deficient cells. Cell Death Differ 17: 1335-1344.
7. Chiaradonna F, Sacco E, Manzoni R, Giorgio M, Vanoni M, Alberghina L. (2006). Ras-dependent carbon metabolism and transformation in mouse fibroblasts. Oncogene 25: 5391-5404.
8. Choo AY, Kim SG, Vander Heiden MG, Mahoney SJ, Vu H, Yoon SO et al. (2010). Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell 38: 487-499.
9. Concannon CG, Tuffy LP, Weisova P, Bonner HP, Davila D, Bonner C et al. (2010). AMP kinase-mediated activation of the BH3-only protein Bim couples energy depletion to stress-induced apoptosis. J Cell Biol 189: 83-94.
10. Danial NN, Gramm CF, Scorrano L, Zhang C-Y, Krauss S, Ranger AM et al. (2003). BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 424: 952-956.
11. Danial NN, Walensky LD, Zhang C-Y, Choi CS, Fisher JK, Molina AJA et al. (2008). Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat Med 14: 144-153.
12. De Lena M, Lorusso V, Latorre A, Fanizza G, Gargano G, Caporusso L et al. (2001). Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. Eur J Cancer 37: 364-368.
13. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. (2008). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20.
14. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S et al. (2007). Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci 104: 19345-19350.
15. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G et al. (2006). Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10: 51-64.
16. Di Cosimo S. (2003). Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today (Barc) 39: 157-174.
17. DiPaola RS, Dvorzhinski D, Thalasila A, Garikapaty V, Doram D, May M et al. (2008). Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapy. Prostate 68: 1743-1752.
18. Dwarakanath BS, Singh S, Jain V. (1999). Optimization of tumour radiotherapy: part V-radiosensitization by 2-deoxy-D-glucose and DNA ligand hoechst-33342 in a murine tumour. Indian J Exp Biol 37: 865-870.
19. Dwarkanath BS, Zolzer F, Chandana S, Bauch T, Adhikari JS, Muller WU et al. (2001). Heterogeneity in 2-deoxy-D-glucose-induced modifications in energetics and radiation responses of human tumor cell lines. Int J Radiat Oncol Biol Phys 50: 1051-1061.
20. Egler V, Korur S, Failly M, Boulay JL, Imber R, Lino MM et al. (2008). Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death. Clin Cancer Res 14: 3132-3140.
21. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR et al. (2004). Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64: 3892-3899.
22. Fan Y, Dickman KG, Zong W-X. (2010). Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J Biol Chem 285: 7324-7333.
23. Frenzel A, Grespi F, Chmelewskij W, Villunger A. (2009). Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis 14: 584-596.
24. Gao P, Tchernyshyov I, Chang T-C, Lee Y-S, Kita K, Ochi T et al. (2009). c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458: 762-765.
25. Geschwind J-FH, Ko YH, Torbenson MS, Magee C, Pedersen PL. (2002). Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 62: 3909-3913.
26. Gonin-Giraud S, Mathieu AL, Diocou S, Tomkowiak M, Delorme G, Marvel J. (2002). Decreased glycolytic metabolism contributes to but is not the inducer of apoptosis following IL-3-starvation. Cell Death Differ 9: 1147-1157.
27. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. (2001). Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochon-drial hexokinase. Genes Dev 15: 1406-1418.
28. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS et al. (2008). AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30: 214-226.
29. Haga N, Naito M, Seimiya H, Tomida A, Dong J, Tsuruo T. (1998). 2-Deoxyglucose inhibits chemotherapeutic drug-induced apoptosis in human monocytic leukemia U937 cells with inhibition of c-Jun N-terminal kinase 1/stress-activated protein kinase activation. Int J Cancer 76: 86-90.
30. Hardie DG. (2007). AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8: 774-785.
31. Hernlund E, Hjerpe E, Avall-Lundqvist E, Shoshan M. (2009). Ovarian carcinoma cells with low levels of beta-F1-ATPase are sensitive to combined platinum and 2-deoxy-D-glucose treatment. Mol Cancer Ther 8: 1916-1923.
32. Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJC et al. (2009). Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 113: 2014-2021.
33. Jain VK, Kalia VK, Sharma R, Maharajan V, Menon M. (1985). Effects of 2-deoxy-D-glucose on glycolysis, proliferation kinetics and radiation response of human cancer cells. Int J Radiat Oncol Biol Phys 11: 943-950.
34. Johnstone RW, Frew AJ, Smyth MJ. (2008). The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8: 782-798.
35. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y et al. (2005). AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18: 283-293.
36. Jones RG, Thompson CB. (2009). Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 23: 537-548.
37. Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B et al. (2010). Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 11: 390-401.
38. Kalia VK, Jain VK, Otto FJ. (1982). Optimization of cancer therapy: part IV-effects of 2-deoxy-D-glucose on radiation induced chromosomal damage in PHA-stimulated peripheral human leukocytes. Indian J Exp Biol 20: 884-888.
39. Kang HT, Hwang ES. (2006). 2-Deoxyglucose: an anticancer and antiviral therapeutic, but not any more a low glucose mimetic. Life Sci 78: 1392-1399.
40. Kaplan O, Navon G, Lyon RC, Faustino PJ, Straka EJ, Cohen JS. (1990). Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism. Cancer Res 50: 544-551. (Pubitemid 20054176)
41. Kaufman RJ, Scheuner D, Schroder M, Shen X, Lee K, Liu CY et al. (2002). The unfolded protein response in nutrient sensing and differentiation. Nat Rev Mol Cell Biol 3: 411-421.
42. Kern KA, Norton JA. (1987). Inhibition of established rat fibrosarco-ma growth by the glucose antagonist 2-deoxy-D-glucose. Surgery 102: 380-385.
43. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS et al. (2004). Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 324: 269-275.
44. Kroemer G, Pouyssegur J. (2008). Tumor cell metabolism: cancer's achilles' heel. Cancer Cell 13: 472-482.
45. Kurtoglu M, Gao N, Shang J, Maher JC, Lehrman MA, Wangpaichitr M et al. (2007). Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol Cancer Ther 6: 3049-3058.
46. Latz D, Thonke A, Juling-Pohlit L, Pohlit W. (1993). Tumor response to ionizing radiation and combined 2-deoxy-D-glucose application in EATC tumor bearing mice: monitoring of tumor size and microscopic observations. Strahlenther Onkol 169: 405-411.
47. Lee YJ, Galoforo SS, Berns CM, Tong WP, Kim HR, Corry PM. (1997). Glucose deprivation-induced cytotoxicity in drug resistant human breast carcinoma MCF-7/ADR cells: role of c-myc and bcl-2 in apoptotic cell death. J Cell Sci 110: 681-686.
48. Liang J, Shao SH, Xu Z-X, Hennessy B, Ding Z, Larrea M et al. (2007). The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autop-hagy or apoptosis. Nat Cell Biol 9: 218-224.
49. Liu H, Savaraj N, Priebe W, Lampidis TJ. (2002). Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (model C). Biochem Pharmacol 64: 1745-1751.
50. Maher J, Krishan A, Lampidis T. (2004). Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol 53: 116-122.
51. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF et al. (2004). 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 64: 31-34.
52. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. (2006). Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 21: 749-760.
53. Michalek RD, Rathmell JC. (2010). The metabolic life and times of a T-cell. Immunol Rev 236: 190-202.
54. Munoz-Pinedo C, Robledo G, Lopez-Rivas A. (2004). Thymidylate synthase inhibition triggers glucose-dependent apoptosis in p53-negative leukemic cells. FEBS Lett 570: 205-210.
55. Munoz-Pinedo C, Ruiz-Ruiz C, Ruiz de Almodovar C, Palacios C, Lopez-Rivas A. (2003). Inhibition of glucose metabolism sensitizes tumor cells to death receptor-triggered apoptosis through enhancement of death-inducing signaling complex formation and apical procaspase-8 processing. J Biol Chem 278: 12759-12768.
56. Murayama A, Ohmori K, Fujimura A, Minami H, Yasuzawa-Tanaka K, Kuroda T et al. (2008). Epigenetic control of rDNA loci in response to intracellular energy status. Cell 133: 627-639.
57. Nakano K, Vousden KH. (2001). PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7: 683-694.
58. Nam SY, Amoscato AA, Lee YJ. (2002). Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway. Oncogene 21: 337-346.
59. Oudard S, Carpentier A, Banu E, Fauchon F, Celerier D, Poupon MF et al. (2003). Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J Neurooncol 63: 81-86.
60. Papaldo P, Lopez M, Cortesi E, Cammilluzzi E, Antimi M, Terzoli E et al. (2003). Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J Clin Oncol 21: 3462-3468.
61. Pathania D, Millard M, Neamati N. (2009). Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv Drug Deliv Rev 61: 1250-1275.
62. Pelicano H, Martin DS, Xu RH, Huang P. (2006). Glycolysis inhibition for anticancer treatment. Oncogene 25: 4633-4646.
63. Pradelli LA, Beneteau M, Chauvin C, Jacquin MA, Marchetti S, Munoz-Pinedo C et al. (2010). Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation. Oncogene 29: 1641-1652.
64. Puthalakath H, O'Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND et al. (2007). ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 129: 1337-1349.
65. Raez LE, Langmuir V, Tolba K, Rocha-Lima CM, Papadopoulos K, Kroll S et al. (2007). Responses to the combination of the glycolytic inhibitor 2-deoxy-glucose (2DG) and docetaxel (DC) in patients with lung and head and neck (H/N) carcinomas. J Clin Oncol 25: 14025.
66. Raez LE, Rosenblatt J, Schlesselman J, Langmuir V, Tidmarsh G, Rocha-Lima C et al. (2005). Combining glycolytic inhibitors with chemotherapy: Phase I trial of 2-deoxyglucose and docetaxel in patients with solid tumors. J Clin Oncol, 2005 ASCO Annu Meet Proc 23: 3190.
67. Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi G et al. (2008). Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci 105: 8215-8220.
68. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB. (2003). Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 23: 7315-7328.
69. Rosbe KW, Brann TW, Holden SA, Teicher BA, Frei III E. (1989). Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro. Cancer Chemother Pharmacol 25: 32-36.
70. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA et al. (2004). The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 101: 3329-3335.
71. Shim H, Chun YS, Lewis BC, Dang CV. (1998). A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci USA 95: 1511-1516.
72. Singh D, Banerji AK, Dwarakanath BS, Tripathi RP, Gupta JP, Mathew TL et al. (2005). Optimizing cancer radiotherapy with 2-deoxy-D-glucose dose escalation studies in patients with glioblasto-ma multiforme. Strahlentherapie und Onkologie 181: 507-514.
73. Singh SP, Singh S, Jain V. (1990). Effects of 5-bromo-2-deoxyuridine and 2-deoxy-D-glucose on radiation-induced micronuclei in mouse bone marrow. Int J Radiat Biol 58: 791-797.
74. Suzuki A, Kusakai G, Kishimoto A, Lu J, Ogura T, Esumi H. (2003). ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation. Oncogene 22: 6177-6182.
75. Swamy RK, Manickam J, Adhikari JS, Dwarakanath BS. (2005). Glycolytic inhibitor, 2-deoxy-D-glucose, does not enhance radiation-induced apoptosis in mouse thymocytes and splenocytes in vitro. Indian J Exp Biol 43: 686-692.
76. Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D'Amelio M et al. (2008). Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 10: 676-687.
77. Taylor RC, Cullen SP, Martin SJ. (2008). Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 9: 231-241.
78. Teicher BA, Herman TS, Holden SA, Epelbaum R, Liu SD, Frei III E. (1991). Lonidamine as a modulator of alkylating agent activity in vitro and in vivo. Cancer Res 51: 780-784.
79. Tennant DA, Duran RV, Gottlieb E. (2010). Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10: 267-277.
80. Thakkar NS, Potten CS. (1993). Inhibition of doxorubicin-induced apoptosis in vivo by 2-deoxy-D-glucose. Cancer Res 53: 2057-2060.
81. Tomida A, Yun J, Tsuruo T. (1996). Glucose-regulated stresses induce resistance to camptothecin in human cancer cells. Int J Cancer 68: 391-396.
82. Tong X, Zhao F, Mancuso A, Gruber JJ, Thompson CB. (2009). The glucose-responsive transcription factor ChREBP contributes to glucose-dependent anabolic synthesis and cell proliferation. Proc Natl Acad Sci 106: 21660-21665.
83. Uyeda K, Repa JJ. (2006). Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab 4: 107-110.
84. Vander Heiden MG, Cantley LC, Thompson CB. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033.
85. Vander Heiden MG, Plas DR, Rathmell JC, Fox CJ, Harris MH, Thompson CB. (2001). Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol 21: 5899-5912.
86. Vousden KH, Ryan KM. (2009). p53 and metabolism. Nat Rev Cancer 9: 691-700.
87. Wang X, Proud CG. (2009). Nutrient control of TORC1, a cell-cycle regulator. Trends in Cell Biol 19: 260-267.
88. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. (2009). ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324: 1076-1080.
89. Wood TE, Dalili S, Simpson CD, Hurren R, Mao X, Saiz FS et al. (2008). A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol Cancer Ther 7: 3546-3555.
90. Xu R-h, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN et al. (2005). Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65: 613-621.
91. Yamada M, Tomida A, Yun J, Cai B, Yoshikawa H, Taketani Y et al. (1999). Cellular sensitization to cisplatin and carboplatin with decreased removal of platinum-DNA adduct by glucose-regulated stress. Cancer Chemother Pharmacol 44: 59-64.
92. Yang C, Sudderth J, Dang T, Bachoo RG, McDonald JG, DeBerardinis RJ. (2009). Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 69: 7986-7993.
93. Yi CH, Sogah DK, Boyce M, Degterev A, Christofferson DE, Yuan J. (2007). A genome-wide RNAi screen reveals multiple regulators of caspase activation. J Cell Biol 179: 619-626.
94. Youle RJ, Strasser A. (2008). The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59.
95. Yun J, Tomida A, Nagata K, Tsuruo T. (1995). Glucose-regulated stresses confer resistance to VP-16 in human cancer cells through a decreased expression of DNA topoisomerase II. Oncol Res 7: 583-590.
96. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. (2007). Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 178: 93-105.
97. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. (1996). Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87: 619-628.
98. Zhang XD, Deslandes E, Villedieu M, Poulain L, Duval M, Gauduchon P et al. (2006). Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro. Anticancer Res 26: 3561-3566.
99. Zhao S, Xu W, Jiang W, Yu W, Lin Y, Zhang T et al. (2010). Regulation of cellular metabolism by protein lysine acetylation. Science 327: 1000-1004.
100. Zhao Y, Altman BJ, Coloff JL, Herman CE, Jacobs SR, Wieman HL et al. (2007). Glycogen synthase kinase 3alpha and 3beta mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Mol Cell Biol 27: 4328-4339.
101. Zhao Y, Coloff JL, Ferguson EC, Jacobs SR, Cui K, Rathmell JC. (2008). Glucose metabolism attenuates p53 and Puma-dependent cell death upon growth factor deprivation. J Biol Chem 283: 36344-36353. M803580200.